{"DataElement":{"publicId":"3395746","version":"1","preferredName":"Pills Remaining Eflornithine Count","preferredDefinition":"Total number of Eflornithine/placebo pills remaining.","longName":"3395745v1.0:2188893v1.0","context":"SWOG","contextVersion":"1","DataElementConcept":{"publicId":"3395745","version":"1","preferredName":"Pills Remaining Eflornithine","preferredDefinition":"Eflornithine/placebo pills remaining.","longName":"3395728v1.0:2433945v1.0","context":"SWOG","contextVersion":"1","ObjectClass":{"publicId":"3395728","version":"1","preferredName":"Eflornithine Pills","preferredDefinition":"A difluoromethylated ornithine compound with antineoplastic activity.  Eflornithine irreversibly inhibits ornithine decarboxylase, an enzyme required for polyamine biosynthesis, thereby inhibiting the formation and proliferation of tumor cells. Polyamines are involved in nucleosome oligomerization and DNA conformation, creating a chromatin environment that stimulates neoplastic transformation of cells. This agent has been shown to induce apoptosis in leiomyoma cells. (NCI04):A dose of medicine in the form of a small pellet.","longName":"C226:C25394","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eflornithine","conceptCode":"C226","definition":"A difluoromethylated ornithine compound with antineoplastic activity.  Eflornithine irreversibly inhibits ornithine decarboxylase, an enzyme required for polyamine biosynthesis, thereby inhibiting the formation and proliferation of tumor cells. Polyamines are involved in nucleosome oligomerization and DNA conformation, creating a chromatin environment that stimulates neoplastic transformation of cells. This agent has been shown to induce apoptosis in leiomyoma cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pill Dosage Form","conceptCode":"C25394","definition":"A solid composed of a small, round object composed of active and/or inert ingredient(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA223546-5766-9D8F-E040-BB89AD434EF7","latestVersionIndicator":"Yes","beginDate":"2012-02-29","endDate":null,"createdBy":"SMITHA","dateCreated":"2012-02-29","modifiedBy":"ONEDATA","dateModified":"2012-02-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2433945","version":"1","preferredName":"Remaining","preferredDefinition":"Remaining; enduring or persisting.","longName":"C25649","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Remaining","conceptCode":"C25649","definition":"Enduring or persisting; residual, left over or behind.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06674CCB-CDFD-04A9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA228405-D2A6-608B-E040-BB89AD432912","latestVersionIndicator":"Yes","beginDate":"2012-02-29","endDate":null,"createdBy":"SMITHA","dateCreated":"2012-02-29","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"5/16/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2188893","version":"1","preferredName":"Pills Remaining Count","preferredDefinition":"the numeric count of tablets remaining.","longName":"PILLS_RMNG_NUM","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2261845","version":"1","preferredName":"Count","preferredDefinition":"To determine the number or amount of something; the result of this activity.","longName":"C25463","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Count","conceptCode":"C25463","definition":"Determining the number or amount of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"FBB87F7A-646B-1AFC-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-13","modifiedBy":"ONEDATA","dateModified":"2005-07-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5B67FF1-49F1-3D18-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-10-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-10-05","modifiedBy":"CAMPBELB","dateModified":"2008-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Total number of eflornithine/","type":"Preferred Question Text","description":"Total number of eflornithine/placebo pills participant brought in to the current visit","url":null,"context":"SWOG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA228405-D2B7-608B-E040-BB89AD432912","latestVersionIndicator":"Yes","beginDate":"2012-02-29","endDate":null,"createdBy":"SMITHA","dateCreated":"2012-02-29","modifiedBy":"SCOTTM","dateModified":"2013-11-07","changeDescription":"5/16/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}